Skip to main content

Pfizer Inc. (PFE)

NYSE: PFE · IEX Real-Time Price · USD
-0.02 (-0.05%)
After-hours:Oct 15, 2021 7:59 PM EDT
-0.18 (-0.43%)
At close: Oct 15, 4:00 PM
Market Cap232.62B
Revenue (ttm)51.64B
Net Income (ttm)13.23B
Shares Out5.60B
EPS (ttm)2.34
PE Ratio17.72
Forward PE10.75
Dividend$1.54 (3.71%)
Ex-Dividend DateNov 4, 2021
Previous Close41.67
Day's Range41.38 - 42.03
52-Week Range32.74 - 51.86
Price Target46.58 (+12.3%)
Est. Earnings DateNov 2, 2021

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brand...

CEOAlbert Bourla
Stock ExchangeNYSE
Ticker SymbolPFE
Full Company Profile

Financial Performance

In 2020, Pfizer's revenue was $41.91 billion, an increase of 1.79% compared to the previous year's $41.17 billion. Earnings were $9.62 billion, a decrease of -40.91%.

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for Pfizer stock is "Hold." The 12-month stock price forecast is 46.58, which is an increase of 12.27% from the latest price.

Price Target
(12.27% upside)
Analyst Consensus: Hold


Europe Recommends Pfizer Boosters for Ages 18 and Up: Could the U.S. Soon Follow?

It depends mainly on the number of breakthrough cases of COVID-19.

13 hours ago - The Motley Fool

3 COVID-19 Pill Stocks to Watch

These big drugmakers could soon compete against each other with oral COVID-19 therapies.

Other symbols:MRK
16 hours ago - The Motley Fool

Better COVID-19 Stock: Merck or Pfizer?

Here's how the two big-pharma stocks stack up against each other.

Other symbols:MRK
16 hours ago - The Motley Fool

We're at a very delicate time in this pandemic: FDA advisory panel member

Dr. Ofer Levy, a voting member of the FDA vaccine advisory panel, joins Closing Bell to discuss the panel's decision to recommend a booster dose of Johnson & Johnson's Covid vaccine.

Other symbols:BNTXJNJMRNA
1 day ago - CNBC Television

Is Pfizer's Stock Overvalued Or Undervalued?

Pfizer Inc. (NYSE: PFE) shares have lagged the S&P 500 in 2021, generating a year-to-date total return of 16.6%. Pfizer has gotten plenty of headlines for its COVID-19 vaccine, but investors may be wond...

1 day ago - Benzinga

Pfizer's Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermat...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recomme...

1 day ago - Business Wire

Pfizer's Next mRNA Vaccine Candidate Goes Beyond COVID-19

Pfizer has expanded its mRNA program into a new area.

1 day ago - The Motley Fool

3 Top Stocks Under $100

Here are three companies for long-term investors to consider this month.

Other symbols:SFIXTTD
1 day ago - The Motley Fool

Could Johnson & Johnson's Booster Opportunity Be Better Than Pfizer's and Moderna's?

The bar could be lower for the FDA to authorize booster shots for J&J's COVID-19 vaccine.

Other symbols:JNJMRNA
1 day ago - The Motley Fool

Cathie Wood Just Bought Shares of This Vaccine Underdog. Should You?

The company disappointed last year, but things may be turning around.

Other symbols:ARCTMRNA
1 day ago - The Motley Fool

Best Single Trading Day in Months for Dow, Nasdaq, S&P

The indexes had been trying to turn around a steep drop to the start of the week, and finally managed on Thursday.

2 days ago - Zacks Investment Research

Pfizer or Alcoa? #AskHalftime

The "Halftime Report" traders answer viewer questions in #AskHalftime.

Other symbols:AA
2 days ago - CNBC Television

Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?

Is (PFE) Outperforming Other Medical Stocks This Year?

2 days ago - Zacks Investment Research

Pfizer Just Scored Another Key Regulatory Approval

Pfizer's Cibinqo snagged an approval in Japan to treat patients with eczema.

2 days ago - The Motley Fool

J&J Covid-19 Vaccine Recipients May Benefit More From Pfizer Or Moderna Boosters, Study Finds

J&J recipients who were administered Moderna or Pfizer boosters showed significantly higher antibody counts compared to those who received a booster of the same vaccine.

Other symbols:JNJMRNA
2 days ago - Forbes

Pfizer Whale Trades Spotted

Someone with a lot of money to spend (and possibly insider knowledge) has taken a bullish stance on Pfizer(NYSE:PFE). And retail traders should know.

3 days ago - Benzinga

Can Pfizer Beat Moderna in mRNA Vaccines?

Pfizer is expanding beyond its coronavirus vaccine.

Other symbols:MRNA
3 days ago - The Motley Fool

Pre-Markets Back to Green Ahead of Economic & Earnings Data

After a down day yesterday, we see the Dow +30 points, the S&P 500 +3 points and the Nasdaq +33.

4 days ago - Zacks Investment Research

Markets Await Economic and Earnings Data

Markets Await Economic and Earnings Data

4 days ago - Zacks Investment Research

How Could Pfizer Be Affected by Moderna's Vaccine Safety Issues?

Rare heart inflammation issues with Moderna's vaccine could work to Pfizer's advantage -- but only slightly.

Other symbols:MRNA
4 days ago - The Motley Fool

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

Pfizer (PFE) closed at $42.06 in the latest trading session, marking a -0.92% move from the prior day.

5 days ago - Zacks Investment Research

Pfizer (PFE) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

5 days ago - Zacks Investment Research

4 Key Things Investors Should Know About Pfizer's Experimental COVID-19 Pill

Pfizer might not be far behind Merck in launching a COVID-19 pill.

5 days ago - The Motley Fool

7 Top Stocks That Held Up Well During This Recent Market Bloodbath

These seven top stocks are among my top picks for investors seeking exposure to companies with the ability to ride out market turmoil. The post 7 Top Stocks That Held Up Well During This Recent Market B...

5 days ago - InvestorPlace